NASDAQ:CLLS - Cellectis Stock Price, Price Target & More

$29.71 -0.34 (-1.13 %)
(As of 04/22/2018 10:22 AM ET)
Previous Close$29.71
Today's Range$29.56 - $30.02
52-Week Range$21.25 - $38.85
Volume90,593 shs
Average Volume637,604 shs
Market Capitalization$1.24 billion
P/E Ratio-10.69
Dividend YieldN/A
Beta1.86

About Cellectis (NASDAQ:CLLS)

Cellectis logoCellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Debt-to-Equity RatioN/A
Current Ratio7.43%
Quick Ratio7.42%

Price-To-Earnings

Trailing P/E Ratio-10.69
Forward P/E Ratio-11.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.72 million
Price / Sales36.65
Cash FlowN/A
Price / CashN/A
Book Value$7.96 per share
Price / Book3.73

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-99,360,000.00
Net Margins-298.01%
Return on Equity-35.63%
Return on Assets-30.10%

Miscellaneous

Employees122
Outstanding Shares41,600,000

How to Become a New Pot Stock Millionaire

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis (NASDAQ:CLLS) posted its earnings results on Monday, March, 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12. The biotechnology company had revenue of $6.91 million for the quarter, compared to analysts' expectations of $10.10 million. Cellectis had a negative return on equity of 35.63% and a negative net margin of 298.01%. View Cellectis' Earnings History.

When is Cellectis' next earnings date?

Cellectis is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Cellectis.

What price target have analysts set for CLLS?

6 equities research analysts have issued 1-year price objectives for Cellectis' stock. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $44.00 in the next year. View Analyst Ratings for Cellectis.

Who are some of Cellectis' key competitors?

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:
  • Dr. André Choulika Ph.D., Co-Founder, Chairman and Chief Exec. Officer (Age 53)
  • Dr. David J. D. Sourdive Ph.D., Co-Founder, Exec. VP - Technical Operations and Director (Age 51)
  • Mr. Eric Dutang, Chief Financial Officer (Age 44)
  • Ms. Elsy Boglioli, Chief Operating Officer
  • Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 55)

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Has Cellectis been receiving favorable news coverage?

Press coverage about CLLS stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectis earned a media sentiment score of 0.03 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $29.71.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.24 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 122 workers across the globe.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS LLE-DE-FRANCE I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]


MarketBeat Community Rating for Cellectis (CLLS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellectis (NASDAQ:CLLS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Cellectis in the last 12 months. Their average twelve-month price target is $44.00, suggesting that the stock has a possible upside of 48.10%. The high price target for CLLS is $73.00 and the low price target for CLLS is $20.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.832.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.00$44.00$39.8333$40.00
Price Target Upside: 48.10% upside25.36% upside39.13% upside39.91% upside

Cellectis (NASDAQ:CLLS) Consensus Price Target History

Price Target History for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2018GuggenheimInitiated CoverageNeutral -> NeutralHighView Rating Details
3/14/2018NomuraBoost Price TargetBuy$73.00HighView Rating Details
12/28/2017OppenheimerReiterated RatingOutperform$40.00 -> $40.00LowView Rating Details
10/29/2017Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
10/6/2017SunTrust BanksReiterated RatingHold$20.00N/AView Rating Details
9/5/2017Wells FargoReiterated RatingOutperform -> Outperform$33.00 -> $40.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$49.00N/AView Rating Details
11/24/2016Piper JaffraySet Price TargetBuy$41.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Cellectis (NASDAQ:CLLS) Earnings History and Estimates Chart

Earnings by Quarter for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS) Earnings Estimates

2018 EPS Consensus Estimate: ($2.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.71)($0.59)($0.65)
Q2 20182($0.72)($0.68)($0.70)
Q3 20182($0.76)($0.68)($0.72)
Q4 20182($0.78)($0.67)($0.73)

Cellectis (NASDAQ CLLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
3/12/2018Q4 2017($0.64)($0.76)$10.10 million$6.91 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.57)($0.73)$10.56 million$7.25 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.59)($0.74)$10.30 million$8.96 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.56)($0.56)$9.52 million$10.30 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.34)($0.38)$9.65 million$13.02 millionViewN/AView Earnings Details
11/22/2016Q3 2016($0.90)($0.40)$9.74 million$12.62 millionViewN/AView Earnings Details
9/8/2016Q2 2016($0.64)($0.20)$8.02 million$20.49 millionViewN/AView Earnings Details
5/11/2016Q1 2016($0.35)($0.92)$7.78 million$10.48 millionViewN/AView Earnings Details
3/14/2016Q4 2015($0.06)$0.25$5.72 million$31.97 millionViewN/AView Earnings Details
11/16/2015Q215($0.43)($0.40)$1.23 million$11.10 millionViewN/AView Earnings Details
9/8/2015Q2 2015($0.64)($0.70)$2.37 million$8.85 millionViewN/AView Earnings Details
6/9/2015Q1 2015$0.26$10.29 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cellectis (NASDAQ:CLLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cellectis (NASDAQ CLLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.41%
Institutional Ownership Percentage: 20.30%
Insider Trading History for Cellectis (NASDAQ:CLLS)
Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ CLLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Cellectis (NASDAQ CLLS) News Headlines

Source:
DateHeadline
Should Cellectis SA.’s (EPA:ALCLS) Recent Earnings Decline Worry You?Should Cellectis SA.’s (EPA:ALCLS) Recent Earnings Decline Worry You?
finance.yahoo.com - April 18 at 8:43 AM
Cellectis (CLLS) Downgraded by BidaskClub to "Hold"Cellectis (CLLS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 16 at 10:55 AM
Zacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.53 MillionZacks: Analysts Anticipate Cellectis (CLLS) Will Announce Quarterly Sales of $9.53 Million
www.americanbankingnews.com - April 16 at 4:58 AM
Cellectis (CLLS) Given Average Rating of "Hold" by AnalystsCellectis (CLLS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 1:39 AM
Cellectis (CLLS) Stock Rating Lowered by BidaskClubCellectis (CLLS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM
 Brokerages Anticipate Cellectis (CLLS) Will Post Earnings of -$0.66 Per Share Brokerages Anticipate Cellectis (CLLS) Will Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - April 14 at 3:17 AM
What Should We Expect From Cellectis SA.’s (NASDAQ:CLLS) Earnings Over The Next Few Years?What Should We Expect From Cellectis SA.’s (NASDAQ:CLLS) Earnings Over The Next Few Years?
finance.yahoo.com - April 13 at 8:55 AM
Cellectis Announces Closing of Follow-On OfferingCellectis Announces Closing of Follow-On Offering
finance.yahoo.com - April 10 at 5:09 PM
Cellectis (CLLS) Earns Buy Rating from Jefferies GroupCellectis (CLLS) Earns Buy Rating from Jefferies Group
www.americanbankingnews.com - April 8 at 8:06 PM
Is Cellectis SA Stock a Buy Now?Is Cellectis SA Stock a Buy Now?
finance.yahoo.com - April 7 at 9:04 AM
Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?
finance.yahoo.com - April 6 at 8:55 AM
Cellectis: Monthly Information on Share Capital and Company Voting RightsCellectis: Monthly Information on Share Capital and Company Voting Rights
www.businesswire.com - April 5 at 4:59 PM
Why Micron Technology, Mechel, and Cellectis Slumped TodayWhy Micron Technology, Mechel, and Cellectis Slumped Today
finance.yahoo.com - April 5 at 4:59 PM
Cellectis (CLLS) Announces Launch of $175M Follow-On OfferingCellectis (CLLS) Announces Launch of $175M Follow-On Offering
www.streetinsider.com - April 5 at 10:47 AM
Cellectis down 2% premarket on pricing of follow-on offeringCellectis down 2% premarket on pricing of follow-on offering
seekingalpha.com - April 5 at 10:47 AM
Cellectis (CLLS) Upgraded to Buy at ValuEngineCellectis (CLLS) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
Cellectis to continue CAR T collaboration with Allogene; shares up 18%Cellectis to continue CAR T collaboration with Allogene; shares up 18%
seekingalpha.com - April 3 at 5:09 PM
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate ...Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate ...
www.businesswire.com - April 3 at 8:53 AM
Cellectis, Allogene To Continue Strategic Cancer Immunotherapy CollaborationCellectis, Allogene To Continue Strategic Cancer Immunotherapy Collaboration
www.nasdaq.com - April 3 at 8:53 AM
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T TherapiesCellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
finance.yahoo.com - April 3 at 8:53 AM
Cellectis (CLLS) Stock Rating Upgraded by BidaskClubCellectis (CLLS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
Zacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.66 Per ShareZacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - March 28 at 3:08 AM
BidaskClub Lowers Cellectis (CLLS) to BuyBidaskClub Lowers Cellectis (CLLS) to Buy
www.americanbankingnews.com - March 28 at 12:34 AM
Cellectis (CLLS) Rating Increased to Strong-Buy at BidaskClubCellectis (CLLS) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 26 at 9:57 AM
Cellectis (CLLS) Stock Rating Upgraded by ValuEngineCellectis (CLLS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM
Cellectis (CLLS) Downgraded to "Hold" at BidaskClubCellectis (CLLS) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 23 at 11:20 PM
Cellectis SA (CLLS) Receives Consensus Rating of "Hold" from AnalystsCellectis SA (CLLS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 3:46 AM
What Should Investors Know About Cellectis SA.’s (EPA:ALCLS) Earnings Trend?What Should Investors Know About Cellectis SA.’s (EPA:ALCLS) Earnings Trend?
finance.yahoo.com - March 19 at 8:52 AM
Cellectis (CLLS) Coverage Initiated by Analysts at GuggenheimCellectis (CLLS) Coverage Initiated by Analysts at Guggenheim
www.americanbankingnews.com - March 16 at 2:54 PM
Research Analysts Offer Predictions for Cellectis SAs Q1 2018 Earnings (CLLS)Research Analysts Offer Predictions for Cellectis SA's Q1 2018 Earnings (CLLS)
www.americanbankingnews.com - March 16 at 8:37 AM
Cellectis SA Forecasted to Earn Q1 2018 Earnings of ($0.59) Per Share (CLLS)Cellectis SA Forecasted to Earn Q1 2018 Earnings of ($0.59) Per Share (CLLS)
www.americanbankingnews.com - March 16 at 8:36 AM
Cellectis SA to Post FY2022 Earnings of ($3.89) Per Share, Oppenheimer Forecasts (CLLS)Cellectis SA to Post FY2022 Earnings of ($3.89) Per Share, Oppenheimer Forecasts (CLLS)
www.americanbankingnews.com - March 15 at 3:10 PM
SunTrust Banks Weighs in on Cellectis SAs FY2022 Earnings (CLLS)SunTrust Banks Weighs in on Cellectis SA's FY2022 Earnings (CLLS)
www.americanbankingnews.com - March 15 at 3:10 PM
Cellectis SA (CLLS) to Post Q4 2018 Earnings of ($0.67) Per Share, Jefferies Group ForecastsCellectis SA (CLLS) to Post Q4 2018 Earnings of ($0.67) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 15 at 11:28 AM
Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - March 15 at 8:41 AM
Cellectis (CLLS) Downgraded by BidaskClub to BuyCellectis (CLLS) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 14 at 7:51 PM
Nomura Increases Cellectis (CLLS) Price Target to $73.00Nomura Increases Cellectis (CLLS) Price Target to $73.00
www.americanbankingnews.com - March 14 at 4:44 PM
Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as SuccessorDr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor
finance.yahoo.com - March 13 at 6:57 PM
Cellectis SA.’s (NASDAQ:CLLS) Profit OutlookCellectis SA.’s (NASDAQ:CLLS) Profit Outlook
finance.yahoo.com - March 13 at 8:55 AM
Cellectis Reports 4th Quarter and Full Year 2017 Financial ResultsCellectis Reports 4th Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 6:13 PM
Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual MeetingCellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting
finance.yahoo.com - March 8 at 6:10 PM
[$$] Crispr gene editing ready for testing in humans[$$] Crispr gene editing ready for testing in humans
finance.yahoo.com - March 5 at 8:44 AM
40,000 Shares in Cellectis SA (CLLS) Acquired by Hudson Bay Capital Management LP40,000 Shares in Cellectis SA (CLLS) Acquired by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 3 at 12:50 PM
Cellectis SA (CLLS) Stake Lifted by ARK Investment Management LLCCellectis SA (CLLS) Stake Lifted by ARK Investment Management LLC
www.americanbankingnews.com - February 27 at 4:24 AM
Zacks: Analysts Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 MillionZacks: Analysts Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 Million
www.americanbankingnews.com - February 24 at 9:28 AM
Cellectis SA (CLLS) Receives Consensus Recommendation of "Buy" from BrokeragesCellectis SA (CLLS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 24 at 3:58 AM
 Analysts Expect Cellectis SA (CLLS) Will Post Earnings of -$0.64 Per Share Analysts Expect Cellectis SA (CLLS) Will Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - February 22 at 3:12 AM
BidaskClub Upgrades Cellectis (CLLS) to Strong-BuyBidaskClub Upgrades Cellectis (CLLS) to Strong-Buy
www.americanbankingnews.com - February 17 at 1:40 PM
Cellectis (CLLS) Downgraded by Zacks Investment Research to SellCellectis (CLLS) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - February 14 at 8:18 PM
Financial Analysis: Cellectis (CLLS) vs. Zynerba Pharmaceuticals (ZYNE)Financial Analysis: Cellectis (CLLS) vs. Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - February 13 at 9:12 PM

SEC Filings

Cellectis (NASDAQ:CLLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellectis (NASDAQ:CLLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellectis (NASDAQ CLLS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.